Trial Profile

A real-world study to determine efficacy of bulevirtide with or without PEG-interferon β 2a in HBV/HDV patients

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bulevirtide (Primary) ; Peginterferon alfa-2a (Primary)
Indications Fibrosis; Hepatitis B; Hepatitis D; Liver cirrhosis
Focus Expanded access; Therapeutic Use

Most Recent Events

24 Jun 2023 Results presented at the European Association for the Study of the Liver Congress 2023
24 Jun 2023 Results (n=15) of analysis assessing efficacy and safety of BLV 10 mg daily with or without PEG-IFNalpha 2a for at least 6 months in HBV/HDV non-responder patients to BLV 2 mg presented at the European Association for the Study of the Liver Congress 2023
08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com